Cardiorenal Protection in Type 2 Diabetes: A Systematic Review Comparing Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors

More on GLP-1 receptor agonists

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• Orforglipron matches insulin glargine on cardiovascular safety

  Lancet · 4 Oct 2026

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026